Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
Jorge Cortes, Hagop Kantarjian, Edward D. Ball, John DiPersio, Jonathan E. Kolitz, Hugo F. Fernandez, Mark Goodman, Gautam Borthakur, Maria R. Baer, Meir WetzlerVolume:
118
Year:
2012
Language:
english
Pages:
10
DOI:
10.1002/cncr.26292
File:
PDF, 229 KB
english, 2012